论文部分内容阅读
目的探讨地塞米松联合利妥昔单抗治疗成人原发性免疫性血小板减少症的临床疗效及安全性。方法 34例原发性免疫性血小板减少症成人患者,随机分为观察组16例和对照组18例,观察组给予地塞米松联合小剂量利妥昔单抗治疗,对照组给予大剂量地塞米松治疗,比较2组疗效和不良反应。结果观察组完全有效8例,部分有效5例,总有效率为81.25%;对照组完全有效7例,部分有效5例,总有效率为66.67%;观察组总有效率明显高于对照组(P<0.05);观察组不良反应发生率(18.75%)与对照组(16.67%)比较差异无统计学意义(P>0.05)。结论成人原发性免疫性血小板减少症患者应用地塞米松联合小剂量利妥昔单抗治疗有较高反应率,不良反应可耐受。
Objective To investigate the clinical efficacy and safety of dexamethasone combined with rituximab in the treatment of adult patients with idiopathic thrombocytopenia. Methods Thirty-four adult patients with idiopathic thrombocytopenia were randomly divided into observation group (n = 16) and control group (n = 18). The observation group was given dexamethasone combined with low-dose rituximab. The control group was given high-dose dexamethasone Miscell treatment, the two groups were compared efficacy and adverse reactions. Results The observation group was totally effective in 8 cases, partially effective in 5 cases and total effective rate was 81.25%. The control group was completely effective in 7 cases and partially effective in 5 cases, the total effective rate was 66.67%. The total effective rate in the observation group was significantly higher than that in the control group P <0.05). The incidence of adverse reactions in the observation group (18.75%) was not significantly different from that in the control group (16.67%) (P> 0.05). Conclusion Dexamethasone combined with low dose of rituximab in patients with adult primary immune thrombocytopenia has a higher response rate, and adverse reactions can be tolerated.